Connect with us

News

How IV Infusion Therapy Enhances Women’s Health and Wellbeing

Published

on

Your first encounter with an intravenous infusion might be a negative one. IV is often administered to people who are sick, injured, or undergoing surgery.

But you may be surprised you don’t have to be in poor shape to receive an IV infusion. In fact, several women undergo it to boost their health and wellbeing.

Are you interested in getting IV infusion therapy as a supplemental wellness treatment? Then, read on. This blog will discuss how IV could help enhance your overall health.

What is IV Infusion Therapy?

IV is medically used to prevent or treat dehydration by introducing specially formulated fluids, including vitamins and minerals, through the patient’s veins. These fluids are in a bag attached to a small tube or catheter inserted into the vein. When delivered directly to the bloodstream, IV may be more effective at absorption than oral medications.

IV administration usually happens in hospitals, clinics, infusion centres, or at home. Wherever you prefer, you must have the treatment done in places offering trusted IV therapy services. Not all IV clinics are regulated by the government. So, for safety, look for reputable places and a licensed healthcare professional to administer your IV treatments.

Key Health Concerns IV Infusion Therapy Can Support

There are several good reasons why women consider IV infusion therapy. It could support and treat various health concerns.

Fatigue and Low Energy Levels

Feeling tired so often could be a cause for concern. It could be because of stress, lack of sleep, a poor diet, or vitamin deficiencies. Vitamin therapy through the IV administration of fluids could replenish essential nutrients like B vitamins and iron. You may feel more refreshed and energized after a session.

Hormonal Balance

Experiences such as menstruation, pregnancy, and menopause often lead to shifts in women’s hormones. While most individuals take pills to treat lower-than-normal hormone levels, IV therapy could also help balance them. The method could be more beneficial for you if you’ve had side effects from consuming pills.

Immune System Support

One key benefit of IV infusion therapy for women is that it could improve a poor immune system. During the treatment, you’ll be given a fluid mix known as a Myers’ cocktail, which includes vitamin C, B vitamins, magnesium, and calcium.

IV could also be used for antibiotic therapy. However, this method is typically done to treat bacterial infections in the lungs, brain, tissues, heart, and bones. Intravenous therapy may be better suited for these conditions, especially when oral medications don’t work or you require higher, controlled doses.

Hydration and Skin Health

Proper hydration benefits skin and overall health. However, there can be times when you’re not drinking enough water or have an electrolyte imbalance. IV infusion therapy could aid against dehydration, making your body healthier and your skin more elastic.

Common Types of IV Infusion Therapy for Women

You can choose among the four common types of IV infusion therapy, depending on your health needs.

  • Vitamin C therapy: This type is ideal for individuals with vitamin deficiencies and immune support.
  • NAD+ therapy: Short for nicotinamide adenine dinucleotide, NAD+ therapy could aid in energy production, cellular repair, and anti-aging in women.
  • Hydration therapy: IV hydration therapy is great for supporting people’s recovery after illness, exercise, or travel.
  • Iron infusions: For women with iron deficiencies, iron infusions could boost energy levels and overall health.

Your healthcare provider can determine which type may work best for you and your health condition.

Scientific Evidence and Research

To this day, many scientific studies are going on to research the effects of IV therapy on women. Many have already supported the claims that the treatment prevents dehydration and malnutrition. Some have also highlighted its efficacy in treating certain chronic conditions, like intravenous ketamine for fibromyalgia.

Standardizing IV infusion therapy protocols requires more rigorous, large-scale research. Confirmation of this treatment method’s long-term safety and efficacy, especially for women, also needs to be obtained.

Safety Considerations and Precautions

IV infusion therapy is generally safe, but you still need to be aware of potential risks.

Some people found that they have allergic reactions to intravenous iron. Others experience nerve damage post-therapy. Common side effects also include blood clots and infections.

Certain individuals may not even be considered for IV therapy due to these risks. For example, pregnant or breastfeeding women might be advised to receive another form of supplemental care or medication. People with underlying health conditions like heart disease or kidney issues may undergo IV therapy but with guidance from a doctor.

Is IV Therapy Right for You?

Before you try IV infusion therapy for yourself, you must consult a qualified medical professional. You’ll need to check if you’re suitable for the procedure.

Your doctor will consider several factors for your eligibility, such as your current lifestyle, health goals, and medical history. If they also observe you have certain conditions, like malabsorption problems, they may recommend IV infusion therapy for you.

Conclusion

Ladies can go through a lot in life, and sometimes, a pill or getting more rest isn’t enough. If you’re seeking improved overall health and wellbeing, consider IV infusion therapy.

IV therapy may be effective in treating ailments you’re feeling, such as fatigue, dehydration, or hormonal imbalance. However, it’s wise to talk to a trusted medical professional and undergo the procedure in a reputable clinic. The right team and treatment could make you feel much better in the long run.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fertility

GLP-1 drugs do not increase pregnancy risks, study finds

Published

on

GLP-1 drugs taken before conception were not linked to higher pregnancy risks in new research, which suggested they may even offer some protection.

Women of reproductive age are increasingly prescribed GLP-1 drugs for weight-management support, but the risks and benefits of using them before pregnancy remain poorly understood.

The findings support continuing the use of GLP-1 medicines in women with metabolic risk factors who are considering pregnancy, said Cara Dolin, a maternal-fetal medicine specialist and co-author of the research, which was presented at the Society of Maternal-Fetal Medicine pregnancy meeting in February 2026.

“While there’s more research to be done, this data provides some reassurance that it is not harmful to be taking a GLP-1 if you’re planning a pregnancy, and that having done so may in fact benefit you by optimising your preconception metabolic health.”

The researchers examined electronic medical records for patients with a pre-pregnancy BMI of more than 30 who delivered at more than 20 weeks’ gestation. The data were reviewed for two studies: one assessed the link between pre-pregnancy GLP-1 use and the risk of gestational diabetes, while the second looked at the risk of severe maternal morbidity in patients with obesity.

Women with obesity, diabetes, cardiovascular disease and other cardiometabolic disorders have a higher risk of pregnancy complications including preeclampsia, gestational diabetes, stillbirth, caesarean section and other outcomes. While GLP-1 medicines can help manage these conditions, they are contraindicated during pregnancy, and women are typically advised to stop the medication two months before trying to conceive.

However, stopping the drugs can often lead to rebound weight gain or worsening metabolic health. A 2025 study suggested this rebound worsened some pregnancy outcomes, but the risks and benefits are still poorly understood, Dolin said.

“There is a lot we just don’t know, which is why we wanted to look at our experience here with our Cleveland Clinic patients and see whether taking GLP-1 drugs before pregnancy was causing harm or if it was beneficial and helping patients have healthier pregnancies.”

Researchers analysed data for more than 8,000 women who had obesity but did not have diabetes before they became pregnant. They compared outcomes for 208 women who had been prescribed GLP-1 receptor agonists before pregnancy with those who had not been prescribed the medication.

Women in the GLP-1 group had more risk factors heading into pregnancy. They tended to be older and have a higher body mass index, higher rates of bariatric surgery and chronic high blood pressure, and present earlier for prenatal care.

However, outcomes for the two groups were similar. Researchers found that the GLP-1 group did not have higher rates of gestational diabetes, severe maternal morbidity or other adverse maternal outcomes, suggesting that the medication may have helped mitigate elevated risk factors.

“I think this is a really important signal, and it may reflect that these patients were able to optimise their metabolic health prior to conception.”

“It shows there’s potential to use these drugs in a more targeted way with patients who are planning a pregnancy and have these different comorbidities and obesity.”

While the findings suggest that using GLP-1 drugs before pregnancy may be beneficial in women with metabolic risk factors, having a plan to stop the medicines before conception is essential, Dolin noted. In some cases, patients may be moved to an alternative medication that is safe for pregnancy and can be used to help manage their metabolic health during pregnancy.

Providers with patients who are taking GLP-1 medicines and planning a pregnancy should consider referral to a maternal-fetal medicine specialist for pre-pregnancy counselling.

“We can have a nuanced conversation with the patient about taking the medication, what the benefits are, what the potential risks are, and help them formulate a plan to transition off the medication once they’re ready to start trying to conceive,” she said.

Continue Reading

Cancer

New scan could speed up endometriosis diagnosis

Published

on

Obesity may be a key driver of rising rates of 11 cancers in adults under 50, a study has found.

The 11 cancers were thyroid, multiple myeloma, liver, kidney, gallbladder, colorectal, pancreatic, endometrial, oral, breast and ovarian cancers.

All except oral cancer are known to be linked to excess weight, with researchers saying raised insulin levels and inflammation may play a part.

The findings come from researchers at the Institute of Cancer Research, London and Imperial College London, who analysed national cancer registry data for England from 2001 to 2019.

In England, around 31,000 cancers were diagnosed in people aged 20 to 49 in 2023, equal to roughly one in every 1,000 people. This compares with 244,000 cases in the 50 to 79 age group, where the rate is around one in 100.

Concerns have been growing in recent years over rising rates of cancers such as bowel and ovarian in younger adults.

Among the younger group, breast cancer was the most common, with 8,500 cases, followed by bowel cancer at 3,000 and melanoma skin cancer with 2,800 diagnoses.

For nine of the 11 cancers identified, rates are rising in younger adults but also increasing in older adults, who are much more likely to develop the disease. Bowel and ovarian cancer were the exceptions, rising only in younger age groups.

The researchers found that bowel cancer rates in younger women linked to BMI rose faster, from 0.9 to 1.6 per 100,000 people, than those not linked to BMI, which rose from 6.4 to 9.6 per 100,000 people. Similar patterns were recorded for men.

However, the authors noted that the overall number of cases of BMI-linked bowel cancer in younger women remained lower than those not linked to BMI, suggesting other factors must be contributing to the increase.

Several suspected contributors, including ultra-processed foods, antibiotic use and air pollution, have been proposed in recent years. However, many of these factors have also shown stable or declining trends in the UK, the team said.

Despite the rise in several cancer rates among younger adults over the past two decades, most established risk factors, including smoking, alcohol consumption, red or processed meat intake, low fibre diets and lack of exercise, remained stable or even declined in the period leading up to diagnosis.

This suggests these traditional risk factors are unlikely to account for much of the increase in cancer cases.

By contrast, overweight and obesity, which have increased steadily since 1995, could be key factors in the rise in cases. The team suggested that between 2001 and 2019, around 20 per cent of the increase in bowel cancer was explained by increases in BMI over that period.

However, the researchers said rises in BMI alone are not enough to explain the overall increase in cancer among younger adults in England and that there are likely to be other causes.

Data also suggest around 15 per cent of bowel cancer in younger people could be linked to being overweight or obese, with around 40 to 50 per cent in total linked to the combined effect of known risk factors such as obesity, lack of exercise, alcohol and smoking.

Montse García-Closas, professor at the ICR, said more research was needed, but “we cannot wait to act”.

She told a media briefing: “Our main conclusion is that although BMI is our best clue, much of the increase still remains unexplained, and we’ve done some additional analysis that show that most likely what’s missing is not just a single cause unexplained, but it’s likely a combination of multiple factors that act together.”

Amy Berrington, professor at the ICR, said: “Although rates have been increasing, cancer in young people is still a rare disease.”

Marc Gunter, professor at Imperial, said obesity was a known risk factor for around 19 different cancers.

He added: “For some of these cancers, including colorectal (bowel) cancer, we think this could be partly caused by higher levels of hormones such as insulin, which is often elevated in people with obesity, as well as inflammation.

“We know people with obesity have higher levels of insulin, and insulin is a growth factor and has been linked to cancer.

“In a recent study, we actually found that insulin in particular might be playing a role in early onset colorectal (bowel) cancer, and this is actually an area of very active research at the moment.”

The researchers called for large, long-term studies to identify all the biological and environmental factors that could explain rising cancer rates in young adults.

García-Closas added: “Tackling obesity across all ages, particularly in children and young people, through stronger public health policies and wider access to effective interventions, could slow the rise in cancer and prevent many cancers and must become a national priority.”

Michelle Mitchell, Cancer Research UK’s chief executive, said: “Globally, and in the UK, we’re seeing a small increase in cancer rates in adults under 50.

“The picture is complex and we need more research to understand what’s driving the trend, but this study helps to fill in some gaps.

“Overweight and obesity doesn’t explain the rise in full though. Improvements in detection are likely to also be playing a part, meaning that more people are being diagnosed at a younger age.

“Preventing cancer cases must be a priority for the UK government. Smoking remains a leading cause of cancer in adults under 50, which is why the Tobacco and Vapes Bill receiving royal assent this week is such a historic moment.

“Measures to restrict the advertising and promotion of junk food, introducing mandatory reporting and targets on healthy food sales, and making nutritious food more accessible to everyone would all help people keep a healthy weight.”

Continue Reading

Diagnosis

WHO launches AI tool for reproductive health information

Published

on

The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.

Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.

It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.

WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.

The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.

WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.

Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.

WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.

The launch comes amid wider concern about misinformation in sexual and reproductive health.

A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.

The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.

WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.